NC State Health Director’s Statewide Standing Order
for Pfizer-BioNTech mRNA COVID-19 Vaccine Administration in Patients Ages 5-11 Years
Revised May 20, 2022

**Purpose:** To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) and to administer Pfizer-BioNTech (herein-after Pfizer vaccines) to persons who meet criteria set-forth by the Food and Drug Administration in accordance with FDA Emergency Use Authorization.

**Policy:** This standing order authorizes any North Carolina healthcare provider, in accordance with the conditions of their licensure, or pursuant to orders issued under North Carolina Executive Order 256, or as a covered person under the federal PREP Act functioning as vaccinating providers (collectively “vaccinators”) to administer FDA approved COVID-19 Vaccines and/or COVID-19 vaccines authorized by the FDA through an Emergency Use Authorization (EUA) per conditions of this order.

### COVID-19 Vaccination

<table>
<thead>
<tr>
<th>Condition or Situation</th>
<th>Assessment Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients 5-11 years old presenting for Pfizer COVID-19 primary series or booster vaccination authorized by the FDA through an Emergency Use Authorization (EUA). Per Session Law 2021-110 SECTION 9. G.S. 90-21.5, the parent or legal guardian of the patient (recipient of vaccine) must provide written consent prior to the patient being vaccinated with Pfizer COVID-19 vaccine.</td>
<td></td>
</tr>
</tbody>
</table>

### Assessment Criteria

#### Primary 2-Dose Series under the following situations:

1. Patients, 5-11 years old who presents for Pfizer vaccine for the first or second dose of their 2-dose primary series. If patient is presenting for second dose of Pfizer: ensure that at least 21 days have passed since the first dose was administered.

#### Primary Series Third Dose under the following situations:

- Patients 5-11 years old, who self-attest or whose parent/legal guardian attests on their behalf to:
  - Being moderately to severely immunocompromised, who present at least 28 days after their second dose of Pfizer vaccine and are presenting for the third dose of their three-dose primary series of Pfizer vaccine.

**For patients who received their primary series of COVID-19 vaccination with a non-FDA authorized or approved vaccine who self-identify as moderately to severely immunocompromised and present requesting an additional dose of Pfizer, refer to section on “Special Circumstances.”**

**NOTE:** Patients should receive the age-appropriate formulation of Pfizer based on the age they are the day of vaccination.

#### Booster dose under the following situations:

Patients 5-11 years old who are not immunocompromised presenting for a booster dose and received 2 previous doses of Pfizer-BioNTech COVID-19 Vaccine at least 5 months ago; or moderately to severely immunocompromised and received their third primary series dose at least 3 months ago.
NC State Health Director’s Statewide Standing Order
for Pfizer-BioNTech mRNA COVID-19 Vaccine Administration in Patients Ages 5-11 Years
Revised May 20, 2022

<table>
<thead>
<tr>
<th>Minimum Dose Intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1 to Dose 2 of Pfizer</td>
</tr>
<tr>
<td>*Dose 2 to Dose 3 of Pfizer</td>
</tr>
<tr>
<td>End of primary series to Booster dose of Pfizer for immunocompetent</td>
</tr>
<tr>
<td>End of primary series to Booster dose of Pfizer for moderately to severely immunocompromised</td>
</tr>
</tbody>
</table>

* see the section above on third doses to determine if a three-dose primary series is appropriate.

Plan of Care

Patient Education and Data Collection
Prior to patients receiving the COVID-19 vaccine, the vaccinator or designee (if delegation permitted by licensure and/or law) shall provide anticipatory guidance regarding vaccination to the patient and parent/legal guardian, which at a minimum shall include:

1. Vaccinators may review suggested comfort holds or embraces with the patient and their parent/legal guardian to reduce stress and facilitate vaccine administration, if applicable.
2. Where, how, and when to obtain follow-up COVID-19 vaccinations, as appropriate and as outlined above.
3. CDC Pre-Vaccination Checklist for COVID-19 Vaccine
4. Fact Sheet for Recipients and Caregivers About the Pfizer COVID-19 Vaccine for Use in Individuals 5-11 Years of Age
5. V-safe information sheet to vaccine recipients and their parent/legal guardian and encourage vaccine recipients to participate in V-safe.

Pfizer COVID-19 Vaccination Administration Procedures

1. Review Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.
2. Review the Fact Sheets for Healthcare Providers Administering Vaccine (Vaccination Providers) for Pfizer for 5-11 Years of Age. The Pfizer-BioNTech COVID-19 Vaccine authorized for use in children 5 through 11 years of age should not be used interchangeably with COMIRNATY® (COVID-19 Vaccine, mRNA)
3. Appropriate medical treatment and clinical staff able to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of mRNA COVID-19 vaccine.
4. A medical provider, defined as a physician, physician assistant, nurse practitioner, or a pharmacist authorized to order COVID-19 vaccines by the PREP Act must be accessible to provide medical supervision of the vaccination site/service, to assess and
**NC State Health Director’s Statewide Standing Order**  
for Pfizer-BioNTech mRNA COVID-19 Vaccine Administration in Patients Ages 5-11 Years  
**Revised May 20, 2022**

<table>
<thead>
<tr>
<th><strong>Vaccine Product &amp; Preparation:</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Vaccine product:</strong> ensure the appropriate Pfizer formulation is selected. Pfizer COVID-19 vaccine for use as primary series and booster in ages 5-11 (10 µg) has an <strong>ORANGE</strong> cap and label and is marked “Age 5y to &lt;12y”. Using gray or purple cap formulations for ages 12 and older (30 µg) may result in vaccine administration errors and should not be used in this age group.</td>
<td></td>
</tr>
<tr>
<td><strong>2. Preparation:</strong> Mix, observing aseptic technique, according to the manufacturer’s instructions. Follow manufacturer’s guidance for storing/handling mixed vaccine. Refer to <a href="#">Pfizer Vaccine Preparation Summary for 5-11 Year Formulation</a>.</td>
<td></td>
</tr>
<tr>
<td><strong>3. Dosing:</strong></td>
<td></td>
</tr>
<tr>
<td>a. Administer 0.2mL (10 µg) Pfizer COVID-19 vaccine to patients aged 5-11 regardless of whether the patient is receiving a first, second, third (for immunocompromised) or booster dose.</td>
<td></td>
</tr>
</tbody>
</table>

-evaluate individuals who present with contraindications or precautions to vaccination, and to answer questions or address problems with carrying out this standing order. This may be telephone or virtual accessibility.

5. Review *Special Circumstances, Precautions, Contraindications,* and *Criteria or Circumstances for Notifying Medical Provider* sections of this standing order **before** administering the COVID-19 vaccine.

6. Following the current [CDC Pre-Vaccination Checklist for COVID-19 Vaccines](#), instruct patients accordingly or consult with overseeing provider.

   a. The pre-vaccination checklist shall be followed with the following exception: COVID-19 vaccination should **not** be deferred in patients who received treatment with convalescent plasma.

7. Written consent must be obtained from the patient’s parent or legal guardian prior to vaccine administration per agency policy and in accordance with NC General Statute 90-21.13 and NC General Statute 90-21.5 and [Session Law 2021-110](#).

8. Personal Protective Equipment: Before administering the COVID-19 vaccination, don appropriate personal protective equipment (PPE) per [CDC guidelines for COVID-19 vaccinations](#) to protect against the transmission of COVID-19.
**NC State Health Director’s Statewide Standing Order**

*for Pfizer-BioNTech mRNA COVID-19 Vaccine Administration in Patients Ages 5-11 Years*

**Revised May 20, 2022**

b. Use only the age-appropriate Pfizer product/dose based on patient age the day they present for vaccination.

c. Inadvertent administration of an incorrect/inappropriate dose or formulation of COVID-19 vaccine, review Interim Clinical Considerations, Appendix C for COVID-19 vaccine errors and deviations, and take action as directed.

### 4. Timing:

All recommended doses of COMIRNATY/Pfizer shall be administered as close to the recommended interval as possible. Doses that are given up to 4 days (the “grace period”) before the recommended interval are valid and should not be repeated. The 4-day grace period shall not be used to prospectively schedule or administer a COVID-19 vaccine dose earlier than recommended. (See interval table above)

a. See Interim Clinical Considerations, Appendix C for information on COVID-19 vaccine errors and administration deviations.

### 5. Administration:

a. **Route of Administration:** Administer Pfizer vaccine by intramuscular (IM) injection in the deltoid muscle of the arm to patients 5-11 years of age. The deltoid muscle is the preferred IM injection site for this age group. If contraindications exist to using the deltoid, the anterolateral thigh also can be used.

b. **Needle Gauge:** Changing needles between drawing up vaccine from a vial and injecting it into a patient is not necessary unless the needle has been damaged, contaminated, or if the needle used to draw up the vaccine is not the correct size for the patient based on their age. See needle sizing chart below:

<table>
<thead>
<tr>
<th>Age of Patient</th>
<th>Needle Gauge</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-10 years old</td>
<td>16-25 mm</td>
<td>*5/8-1 inch</td>
<td>Deltoid muscle</td>
</tr>
<tr>
<td></td>
<td>25-32 mm</td>
<td>1-1.25 inches</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>11 years old</td>
<td>16-25 mm</td>
<td>*5/8-1 inch</td>
<td>Deltoid muscle</td>
</tr>
<tr>
<td></td>
<td>25-38 mm</td>
<td>1-1.25 inches</td>
<td>Anterolateral thigh</td>
</tr>
</tbody>
</table>

* A 5/8 inch needle may be used in patients weighing less than 130lbs in the deltoid only if subcutaneous tissues are not bunched and injection is made at 90-degree angle.

c. **Multiple vaccinations:** If multiple vaccines are administered at a single visit, administer each injection in a different injection site following guidance in the CDC Interim Clinical Considerations. Injection sites should be separated by at least 1 inch.

i. In patients who are 11 years old, the deltoid muscle can be used.

ii. In patients who are 5-10 years old, if more than 2 vaccines are injected in the same limb, the vastus lateralis muscle of the anterolateral thigh is the preferred site due to greater muscle mass.
**NC State Health Director’s Statewide Standing Order**
for Pfizer-BioNTech mRNA COVID-19 Vaccine Administration in Patients Ages 5-11 Years
**Revised May 20, 2022**

<table>
<thead>
<tr>
<th>d. Bleeding Risk:</th>
<th>Patients with blood disorders or who are on blood thinners: administer the vaccine using a 23 gauge or smaller caliber needle, followed by firm pressure on the site, without rubbing, for at least 2 minutes.</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Documentation:</td>
<td>a. CVMS/NCIR: Document vaccine record in CVMS or NCIR within <strong>24 hours</strong> after vaccine administration per system guidelines found at: <a href="https://immunize.nc.gov/providers/covid-19training.htm">https://immunize.nc.gov/providers/covid-19training.htm</a>. If vaccine is documented in the EHR within 24 hours, providers have no more than <strong>72 hours</strong> from administration to also enter data in CVMS or NCIR. Determining whether to document in CVMS versus NCIR should occur according to site protocol; it is not necessary to document in both systems.</td>
</tr>
<tr>
<td></td>
<td>b. <strong>Electronic Medical Record</strong>: If necessary for billing or other purposes, document patient COVID-19 vaccination in agency electronic medical record per agency policy.</td>
</tr>
<tr>
<td></td>
<td>c. Provide vaccine recipients and their parent/legal guardian with COVID-19 Vaccination Record Card indicating the vaccine dose number, product name/manufacturer, lot number, date of vaccination, name/location of vaccinator and clinic site.</td>
</tr>
<tr>
<td></td>
<td>d. Counsel when and how patient needs to schedule return appointment for second or third dose-of COVID-19 vaccine, if applicable.</td>
</tr>
</tbody>
</table>

**Pfizer COVID-19 Vaccination Observation and Follow-Up**

1. **Post-vaccination Observation**: Nurses, EMS, or other individuals who are trained and supervised by clinical staff shall observe patients post-vaccination for immediate allergic reactions according to the [Centers for Disease Control and Prevention guidelines](https://www.cdc.gov/vaccines/health-providers/post_vaccination_observation.html) for the following time periods:
   a. **30 minutes**:
      i. Persons with a history of an immediate allergic reaction of any severity to a non-COVID-19 vaccine
      ii. Persons with a history of anaphylaxis due to any cause
      iii. People with a contraindication to a different type of COVID-19 vaccine (for example, people with a contraindication to a viral vector vaccine-Janssen/Johnson and Johnson who receive a mRNA vaccine-COMIRNATY/Pfizer or Moderna/SPikevax) should be observed for 30 minutes following vaccination.
      iv. Persons with an immediate (within 4 hours of exposure) non-severe allergic reaction to a COVID-19 vaccine or injectable therapy
   b. **15 minutes**: All other persons

2. **Anaphylaxis Management**: Be prepared to manage medical emergencies by following your emergency response policies, procedures, and standing orders for any vaccine reaction, which must include appropriate equipment and medications (e.g., epinephrine,
NC State Health Director’s Statewide Standing Order  
for Pfizer-BioNTech mRNA COVID-19 Vaccine Administration in Patients Ages 5-11 Years  
Revised May 20, 2022

<table>
<thead>
<tr>
<th>dihydrophenhydramine) where vaccines are provided to respond to severe allergic reactions and anaphylaxis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. <strong>Syncope:</strong> Be prepared to manage syncope as it may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from fainting.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Special Circumstances</th>
<th>People who received COVID-19 vaccination outside the United States: The recommendations for people vaccinated outside of the United States depend on the vaccine(s) received for the primary series, whether the primary series was completed, and whether a booster dose was received. Refer to [Interim Clinical Considerations, Appendix A (People who received COVID-19 vaccine outside the United States)] and take action/consult with medical provider as directed.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Participants in clinical trials within or outside the United States</strong> who received all the recommended primary series doses of a WHO-EUL COVID-19 vaccine (i.e., not placebo) that is not FDA-approved or FDA-authorized are considered fully vaccinated. They are also eligible for a booster dose Pfizer-BioNTech COVID-19 Vaccine at least 5 months after completing the Pfizer 2 dose primary series for immune competent children. Those who are moderately to severely immunocompromised should wait at least 3 months after their third primary series dose. In addition, individuals who received a vaccine that is not listed for emergency use by WHO but for which a U.S. data and safety monitoring board or equivalent has independently confirmed efficacy are considered fully vaccinated. *These persons require medical consultation.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Moderately or severely immunocompromised clinical trial participants should receive an additional dose of Pfizer-BioNTech COVID-19 Vaccine after receiving their 2nd dose of a primary series.</td>
</tr>
<tr>
<td></td>
<td>• Clinical trial participants (including moderately or severely immunocompromised people who received a 3-dose primary series) <strong>should</strong> receive a single booster dose of Pfizer-BioNTech COVID-19 Vaccine 3 months after completing the third primary series dose. If clinical trial participants have questions about whether they should receive an additional and/or booster dose outside of the clinical trial, they should consult with their healthcare provider. Clinical trial participants who did not receive all the recommended doses, or who received other vaccines not listed above, should consult with their healthcare provider to determine if they should receive an FDA-approved or FDA-authorized COVID-19 vaccine series.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>Adverse events that occur in a recipient following COVID-19 vaccination should be reported to VAERS. Vaccination providers are required by the FDA to report the following that occur after COVID-19 vaccination under BLA or EUA:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Vaccine administration errors</td>
</tr>
<tr>
<td></td>
<td>Information on preventing, reporting, and managing COVID-19 vaccine administration errors is found in <a href="#">Appendix C. Administration errors should be reported to VAERS</a></td>
</tr>
<tr>
<td></td>
<td>• Serious adverse events</td>
</tr>
<tr>
<td></td>
<td>• Cases of Multisystem Inflammatory Syndrome</td>
</tr>
</tbody>
</table>
**NC State Health Director’s Statewide Standing Order**  
for Pfizer-BioNTech mRNA COVID-19 Vaccine Administration in Patients Ages 5-11 Years  
Revised May 20, 2022

- Cases of COVID-19 that result in hospitalization or death reporting is encouraged for any other clinically significant adverse event, even if it is uncertain whether the vaccine caused the event. Information on how to submit a report to VAERS is available at [https://vaers.hhs.gov](https://vaers.hhs.gov) or by calling 1-800-822-7967.

| Precautions for Use of this Order | 1. Persons with a history of an immediate allergic reaction to any other vaccine other than COVID-19 vaccine or to any injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous immunotherapy for allergies, i.e., “allergy shots”]). This includes people with a history of an immediate allergic reaction to a vaccine or injectable therapy that contains multiple components, one of which is a COVID-19 vaccine component, even if it is unknown which component elicited the immediate allergic reaction.  
2. Persons with a contraindication to one type of a COVID-19 vaccine (e.g., viral vector – Janssen/Johnson and Johnson) have a precaution to another (e.g., mRNA – COMIRNATY/Pfizer or Moderna/SPIKEVAX) because of potential cross-reactive hypersensitivity. Consultation with an allergist-immunologist should be considered prior to vaccination and patients with this precaution should be vaccinated in a health care setting where allergic reactions can be immediately managed and under the supervision of a health care provider experienced in the management of severe allergic reactions.  
3. Patient or parent/legal guardian on their behalf reports moderate to severe acute illness.  
4. Patient or parent/legal guardian on their behalf who report a precaution to vaccination must be counseled about the unknown risks of experiencing a severe allergic reaction and balance these risks against the benefits of vaccination.  
5. Persons with a history of myocarditis or pericarditis.  
6. Persons with a history of MIS-C. |
| Contraindications for Use of this Order | Do not administer the COVID-19 Vaccine to individuals with a history of:  
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the vaccine  
- Immediate allergic reaction of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine.  
[See Appendix C: Interim Clinical Considerations for Use of Covid-19 Vaccines Currently Approved or Authorized in the United States.] |
| Criteria or Circumstances for Notifying Medical Provider | 1. Allergic reaction: Call 911, implement medical emergency protocols and immediately notify the medical provider providing clinical supervision of the vaccination site/service.  
2. Patient or parent/legal guardian on their behalf reports a precaution for the vaccine.  
3. COVID-19 vaccine history cannot be determined or is not available.  
4. Patients vaccinated with COVID-19 vaccines not authorized or approved in the US.  
5. Patients vaccinated with active COVID-19 vaccine as part of a clinical trial.  
6. Patient reports they are a HCT or CAR-T cell recipient. These patients may need revaccination, dependent on when the transplant or therapy occurred. |
NC State Health Director’s Statewide Standing Order
for Pfizer-BioNTech mRNA COVID-19 Vaccine Administration in Patients Ages 5-11 Years
Revised May 20, 2022

7. Notify the Medical Provider from the organization providing clinical supervision of the vaccination site/service at any time there are questions or problems with carrying out this standing order.

Note: Healthcare providers or health departments in the United States can request a consultation from CISA COVIDvax for a complex COVID-19 vaccine safety question that is (1) about an individual patient residing in the United States or vaccine safety issue and (2) not readily addressed by CDC or Advisory Committee on Immunization Practices (ACIP) guidelines.

Approved by: ___
Elizabeth Cuervo Tilson, MD, MPH
NPI: 1760540421

Date Signed: ___5-20-22________

This order is effective immediately upon signing and may be revised or revoked by the State Health Director according to his/her discretion. This order will expire upon rescission off the State of Emergency Executive Order Number 116. Legal Authority: Executive Order 256.